|
Age, years, median (range)
|
59.5 (48–74)
|
|
Sex, male/female, n
|
26/6
|
|
AFP, ng/ml, median (range)
|
3.23 (1.04–64.65)
|
|
AFP > 20 ng/ml, n (%)
|
2 (6.2%)
|
|
CA19-9, U/ml, median (range)
|
12.82 (0.91–866.8)
|
|
CA19-9 > 40 U/ml, n (%)
|
5 (15.6%)
|
|
CEA, ng/ml, median (range)
|
3.12 (0.93–86.67)
|
|
CEA > 8 ng/ml, n (%)
|
5 (15.6%)
|
|
Tumor location, n
| |
|
Ampulla of Vater
|
7
|
|
Stomach
|
25
|
|
Tumor size < 3 cm/>3 cm
|
14/18
|
|
T, n (%)
| |
|
T1
|
1 (3.1%)
|
|
T2
|
6 (18.8%)
|
|
T3
|
16 (50.0%)
|
|
T4
|
9 (28.1%)
|
|
Lymph node metastasis, n (%)
|
24(75.0%)
|
|
TNM stage*, n (%)
| |
|
I
|
2(15.6%)
|
|
II
|
5 (15.6%)
|
|
III
|
24 (65.7%)
|
|
IV
|
1 (3.1%)
|
|
Ki67 median (range)
|
50.0% (10.0–90.0%)
|
|
Cell type of NEC, n (%)
| |
|
Large cell
|
11 (34.4%)
|
|
Mixed cell
|
14 (43.8%)
|
|
Small cell
|
7 (21.8%)
|
|
Lymphatic invasion yes/no
|
27/5
|
|
Angioinvasion yes/no
|
18/14
|
|
Perineural invasion yes/no
|
20/12
|
|
Differentiation of adenocarcinoma, n (%)
| |
|
Well differentiation
|
3 (9.3%)
|
|
Moderate differentiation
|
12 (37.5%)
|
|
Poor differentiation
|
10 (31.3%)
|
|
Signet ring cell/Mucin
|
7 (21.9%)
|
|
Syn (+), n (%)
|
31 (96.9%)
|
|
CgA (+), n (%)
|
26 (81.3%)
|
|
CD56 (+), n (%)
|
18(56.3%)
|
|
EMA(+), n (%)
|
11 (34.4%)
|
|
PCK(+), n (%)
|
18 (56.3%)
|
|
CK7(+), n (%)
|
8 (25.0%)
|
|
Chemotherapy, n (%)
|
11 (34.4%)
|
